MECHELEN, BELGIUM--(Marketwire - January 30, 2013) - Galapagos NV (Euronext: GLPG) announced
today that it has been awarded a EUR2.5 million grant from the Flemish
Innovation by Science and Technology (IWT) for inflammatory bowel disease
research and development. The goal of this 2.5-year project is to
therapeutic compounds for future treatment of IBD patients.
Inflammatory bowel disease (IBD) is a chronic, uncontrolled inflammation
intestinal mucosa. Crohn's disease (CD) and ulcerative colitis (UC) are
main types of IBD; both diseases have an autoimmune component. The
of anti-TNF alpa antibodies has changed the treatment of refractory
but only one third of the patients will achieve long-term remission. As
the medical need in this patient segment is very high.
The general purpose of the IWT-funded program is to gain better insight
roles of GPR43 and two undisclosed targets in the pathobiology of
inflammatory disorders, in order to understand their therapeutic
Galapagos will collaborate in this project with Professor Dr Paul
Professor Dr Séverine Vermeire from the Catholic University of
Leuven, and the
research group of Professor Dr Martine De Vos at Ghent University.
Galapagos has been working in the anti-inflammatory field for a long
has several projects with IBD as potential indication. The first compound
will be tested in IBD patients is GLPG0974, an inhibitor of target GPR43
known as FFA2). This target is one of the three whose role in IBD
investigated in this IWT-funded project. Galapagos has recently
second Phase I clinical study with GLPG0974, and results are expected
reported later this quarter. In April Galapagos will start a Proof of
study with GLPG0974 in UC.
"After RA, IBD is the second autoimmune disease focus for Galapagos. With
grant we will get a better understanding of the cause of IBD, and this
contribute to the search for better medicines," said Piet Wigerinck,
Galapagos. "The knowledge that will come from this research will provide
insight into the potential of our programs for use in this indication."
Inflammatory bowel diseases (IBD) are disorders of multi-factorial cause
present as a multitude of phenotypes, clinical behaviors and severity.
disease (CD) and ulcerative colitis (UC) are the two main types of IBD.
peak age of onset is 15 to 30 years old, with a second, smaller peak
in individuals aged 50 to 70, with the prevalence rate of IBD reaching
The hallmark of IBD is chronic uncontrolled inflammation of the
mucosa, involving a pathological response in both innate and adaptive
system. The pathogenesis is an interplay of factors as diverse as
susceptibility, the external environment, infectious agents, the
enteric microbiota, and (mucosal) immune system dysfunction.
current understanding of the pathogenesis remains limited. The
inflammatory response begins with infiltration of neutrophils and
which release chemokines and cytokines. These in turn exacerbate
dysfunctional immune response and activate cellular and humoral responses
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size clinical
biotechnology company specialized in the discovery and development of
molecule and antibody therapies with a novel mode-of-action. The
progressing four clinical, six pre-clinical, and 30 discovery programs in
fibrosis, inflammation, antibiotics, metabolic disease, and other
Its lead program is GLPG0634, an orally-available, selective inhibitor of
for the treatment of rheumatoid arthritis and potentially other
diseases. In two four-week Phase 2 studies, GLPG0634 showed improvement
signs and symptoms of rheumatoid arthritis and a unique safety profile.
6-month Phase 2b study is expected to start Q2 2013 with topline data
Q4 2014. AbbVie and Galapagos signed a worldwide license agreement
AbbVie will be responsible for further development and commercialization
Phase 2b. Galapagos is also progressing two other clinical development
with clinical readouts expected in 2013: GLPG0187, a novel integrin
antagonist in development for metastasis, is in a Phase 1b patient
GLPG0974 is the first inhibitor of GPR43, which is currently often
as FFA2. It will be evaluated for the treatment of IBD. This program
Phase 1 and a Proof of Concept Phase 2 study will start in Q2 2013.
The Galapagos Group, including fee-for-service companies BioFocus,
Fidelta, has over 800 employees and operates facilities in five countries,
global headquarters in Mechelen, Belgium. Further information about the
and its drug development programs can be found online at: www.glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other
factors which might cause the actual results, financial condition,
or achievements of Galapagos, or industry results, to be materially
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance
such forward-looking statements. These forward-looking statements speak
of the date of publication of this document. Galapagos expressly disclaims
obligation to update any such forward-looking statements in this document
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
Galapagos receives EUR2.5 million IWT grant for IBD research:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE